CytoDyn said on Tuesday that new data supports a new way its lead drug, leronlimab, a CCR5 antagonist, may help treat solid tumors by increasing levels of PD-L1.The findings come from a review of ...

CytoDyn (OTCQB:CYDY) said on Tuesday that data supports a new way its drug leronlimab, a CCR5 antagonist, may help treat solid tumors by increasing levels of PD-L1. The findings come from a review ...

VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the ...

--CytoDyn Inc., a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has lifted the clinical hold ...

VANCOUVER, Washington, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the ...

CytoDyn has withdrawn an approval application for leronlimab in a specific HIV indication, the latest installment in the troubled biotech’s ongoing saga to get the monoclonal antibody to market.

Today the Board of Directors of CytoDyn Inc., a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a leadership ...

Leronlimab, a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system, is a hugely versatile and valuable molecule.

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential ...

VANCOUVER, Washington, March 19, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a ...